Paris-based Cardiawave, a focused ultrasound company with a mission to reduce aortic valve stenosis caused by calcification, will soon begin clinical trials to test its Valvopulse device.
As announced last month, the company seeks to enroll 10 patients in France, the Netherlands, and Serbia during the summer of 2019. Participating hospitals in the multicenter, international study are Georges Pompidou European Hospital in Paris, France, Amphia Hospital in Breda, the Netherlands, and the Clinical Center of Serbia in Belgrade, Serbia. Professor Emmanuel Messas, a cardiologist at the Georges Popidou, will serve as the study’s principal investigator. Valvopulse precisely delivers pulsed, mechanical focused ultrasound to disrupt and soften the calcifications on aortic valve leaflets. The procedure is designed to restore valve mobility and enable the aortic valve to once again open widely –
immediately after the procedure.